ClinicalTrialsFinder
RecruitingNot ApplicableNCT05979064

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

Laparoscopically Harvested Omental Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)

Sponsor

Northwell Health

Enrollment

10 participants

Start Date

Apr 4, 2023

Study Type

INTERVENTIONAL

Conditions

Brain CancerGlioblastomaGBMGliomaGlioblastoma MultiformeGlioma, MalignantHigh Grade GliomaGlioblastoma Multiforme of Brain

Summary

This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

Eligibility

Min Age: 18 Years

Inclusion Criteria18

  • Subject is a male or female 18 years of age or older.
  • Subject is undergoing planned resection of known or suspected GBM.
  • Subject has a Karnofsky Performance Status (KPS) 70% or greater.
  • Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.
  • Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for ≥ 80% resection of enhancing region.
  • Subject must be able to undergo MRI evaluation.
  • Subject meets the following laboratory criteria:
  • White blood count ≥ 3,000/μL
  • Absolute neutrophil count ≥ 1,500/μL
  • Platelets ≥ 100,000/μL
  • Hemoglobin \> 10.0 g/dL (transfusion and/or ESA allowed)
  • Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN
  • Blood urea nitrogen (BUN) and creatinine \< 1.5 x ULN
  • Females of reproductive potential must have a negative serum pregnancy test and be willing to use an acceptable method of birth control.
  • Able to understand and willing to sign an institutional review board (IRB)- approved written informed consent document
  • Subject has a histologically confirmed (frozen section) diagnosis of recurrent WHO Grade IV glioblastoma multiforme (GBM).
  • Omental graft is technically feasible.

Exclusion Criteria11

  • Subject, if female, is pregnant or is breast feeding.
  • Subject intends to participate in another clinical trial.
  • Subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery.
  • Subject has an active infection requiring treatment.
  • Subject has radiographic evidence of multi-focal disease or leptomeningeal dissemination.
  • Subject has a history of other malignancy, unless the patient has been disease- free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as localized prostate carcinoma or cervical carcinoma in situ after curative treatment
  • Subject has a known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection.
  • Subject has a history or evidence of any other clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Subject has had prior abdominal surgery.
  • Subject has severe renal insufficiency rendering gadolinium MRI contraindicated.
  • Subject who are unable to have an MRI scan for any reason.

Interventions

PROCEDURELaparoscopically harvested omental tissue autograft

1. Standard neurosurgical removal of recurrent GBM, 2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically), 3. the omental fat will be transferred and implanted into brain tumor cavity, 4. standard closure of surgical resection cavity.

Locations(1)

Lenox Hill Brain Tumor Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05979064

Related Trials

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT061615191 location

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT073265661 location

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

NCT072256218 locations

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT046786483 locations

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

NCT047320656 locations